

Date: October 29, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Submission of Media Release

Dear Sir/Ma'am,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release in relation to the Un-audited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026 duly approved by the Board of Directors of the Company at their meeting held on October 29, 2026.

You are requested to take the same on your record.

Thanking you.

For Senores Pharmaceuticals Limited

SHILPA SHARMA
Digitally signed by SHILPA SHARMA
DN: cn=SHILPA SHARMA, c=IN,
o=Personal,
email=csshilpa.agarwal@gmail.com
Date: 2026.10.29 14:04:46 +05'30'

Shilpa Sharma
Company Secretary & Compliance Officer
Membership Number: A34516

Enclosure: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

SENORES PHARMACEUTICALS LIMITED

Robust Financial & Operational Performance in Q2 and H1 FY27 Highest-ever quarterly Revenue and EBITDA in Q2FY27

Ahmedabad, Gujarat, 29th October 2026 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its unaudited Financial Result for the quarter and half year ended 30th September 2026.

Q2 FY27 CONSOLIDATED FINANCIAL HIGHLIGHTS

Revenue ₹ 192 crs  +25% Y-o-Y	EBITDA ₹ 58 crs  +38% Y-o-Y	PAT ₹ 37 crs  +22% Y-o-Y
---	---	--

H1 FY27 CONSOLIDATED FINANCIAL HIGHLIGHTS

Revenue ₹ 373 crs  +30% Y-o-Y	EBITDA ₹ 111 crs  +58% Y-o-Y	PAT ₹ 67 crs  +31% Y-o-Y
---	--	--

Q2 & H1 FY27 SEGMENTAL HIGHLIGHTS

Segment Revenue (₹ crs)	Q2FY27	Q2FY26	Y-o-Y	H1FY27	H1FY26	Y-o-Y
Regulated Markets	136.7	106.9	27.9%	264.5	196.9	34.3%
Emerging Markets	38.4	31.7	21.2%	76.0	60.7	25.3%
Branded Generics	9.5	11.9	-20.5%	17.5	20.2	-13.4%
Others	7.8	3.4	126.2%	14.6	8.7	67.2%
Total Revenue	192.3	153.9	24.9%	372.5	286.5	30.0%

Q2 and H1 FY27 PERFORMANCE HIGHLIGHTS

✓ **Consistently strong and broad-based growth across businesses**

- Consistently delivering robust performance. Revenue for Q2 and H1 FY27 growing by **25% and 30% Y-o-Y respectively**.
- Regulated & Emerging Market revenues grew by **34% & 25% respectively** on a Y-o-Y basis in H1.

✓ **Robust improvement in profitability**

- EBIDTA for Q2 and H1 FY27 grew by 38% and 58% with margin expansion of ~290 bps and ~530 bps on a Y-o-Y basis respectively.
- EBITDA could have been even higher but for initial set-up and operating costs associated with Zoraya and Amerisyn, without corresponding revenue generation.

✓ **Continued expansion of product portfolio**

- Nearly doubled our Regulated Markets portfolio, expanding from 34 ANDAs as of September 2025 to 64 ANDAs as of September 2026, out of which 23 ANDAs have been commercialized.

✓ **Improvement in cash flow generation**

- Cash from Operations stood at ₹ 38 crores in H1FY27, consistent improvement in cash flow generation trajectory over the last 12-18 months.

✓ **Emerging Markets on Steady Trajectory**

- Emerging Markets business on a steady growth trajectory. Revenue growing by 21% and 25% Y-o-Y in Q2 and H1 FY27 respectively. Increasing focus on niche products and streamlined go-to-market strategies.

✓ **Outlook remains positive**

- On track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27. This is underpinned by a robust product pipeline, with strong visibility of commercial launches over the course of the year.

Commenting on the performance, **Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said,

“We delivered another robust performance in Q2 and H1 FY27, marking our 9th consecutive quarter of healthy double-digit growth. Strong execution, operational excellence and diversified business operations continue to drive growth and strengthen our business fundamentals.

Our Regulated Markets business sustained strong momentum, with our ANDA portfolio nearly doubling to 64, including 23 commercialized products and 41 planned launches over the next 18–24 months. Strong launch readiness, the scaling up of our Apnar facility, and the upcoming contributions from Zoraya and Amerisyn provide clear growth visibility. Our CDMO/CMO opportunities and pipeline of 41 molecules covering approximately 130 strengths further strengthen our growth platform.

Our Emerging Markets business continued to grow, with improving profitability and positive cash flows. Entry into Europe and the anticipated PIC/S approval for our Chhatral facility are expected to expand market access and support future growth. In India, investments in field-force expansion and market reach position our critical care injectables business for steady progress.

Operating cash flow improved to ₹38 crore in H1 FY27, compared with ₹31 crore in the previous year. While initial costs for Zoraya and Amerisyn temporarily impacted profitability, their anticipated scale-up from FY28 onwards is expected to drive operating leverage and improve margins.

Backed by a robust product pipeline, expanded manufacturing capabilities and strong commercial launch visibility, we remain on track to deliver 30–40% revenue growth and 50–60% PAT growth in FY27, followed by anticipated annual growth of 20–25% over the next two years.”

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 64 ANDAs and 19 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with 558 product registrations and 944 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 3 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant, second in Gujarat, which is also US-FDA approved and the third in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to Emerging Markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact

**Company : SENORES PHARMACEUTICALS LIMITED**

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

**Investor Relations : Strategic Growth Advisors**

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899